Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
- To investigate the safety and tolerability of OPB-31121 following repeated oral
administration of OPB-31121 in patients Non-Hodgkin's Lymphoma(NHL) or Multiple
Myeloma(MM)
- To determine the potential dose-limiting toxicities and maximum-tolerated dose in
patients treated with OPB-31121
- To determine the pharmacokinetics and anti-tumor efficacy of OPB-31121 in patients